5月12日 - ** 药物开发商Moleculin Biotech MBRX.O股价盘前上涨11.4%至1.17美元
** 该公司称，欧洲药品管理局(EMA) 已批准其进行后期研究的申请，以测试其实验性药物 Annamycin
** 安那霉素是治疗急性髓性白血病（血液和骨髓癌的一种）的潜在药物
** 公司预计将在下半年公布后期研究的中期数据
** 安那霉素还获得了美国 FDA 的 (link) "快速通道 "和 "孤儿药 "称号
** 截至上次收盘，MBRX 累计下跌 38.2
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.